12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Apidra insulin glulisine regulatory update

sanofi-aventis received 2 warning letters from FDA regarding the company's failure to adequately address cGMP deficiencies and postmarketing reporting violations identified during FDA inspections last year. The pharma has 15 days from the...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >